Shares of Immune Pharmaceuticals Inc (NASDAQ:IMNP) have been assigned a consensus broker rating score of 3.00 (Hold) from the one brokers that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating. Immune Pharmaceuticals’ rating score has declined by 200% from three months ago as a result of various analysts’ ratings changes.

Zacks has also assigned Immune Pharmaceuticals an industry rank of 108 out of 255 based on the ratings given to its competitors.

Separately, Maxim Group lowered Immune Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, August 6th.

Shares of NASDAQ IMNP remained flat at $$0.07 during mid-day trading on Friday. The stock had a trading volume of 53,383 shares, compared to its average volume of 950,741. The company has a current ratio of 0.31, a quick ratio of 0.31 and a debt-to-equity ratio of 0.15. Immune Pharmaceuticals has a 52 week low of $0.06 and a 52 week high of $1.99.

Immune Pharmaceuticals (NASDAQ:IMNP) last released its quarterly earnings results on Tuesday, August 14th. The biopharmaceutical company reported ($0.71) EPS for the quarter.

Immune Pharmaceuticals Company Profile

Immune Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. The company's lead product candidate is bertilimumab, a human antibody, which is in Phase II clinical trials that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis.

Read More: How to Use the New Google Finance Tool

Get a free copy of the Zacks research report on Immune Pharmaceuticals (IMNP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Immune Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.